^
Association details:
Biomarker:B2M elevation
Cancer:Multiple Myeloma
Drug Class:Proteasome inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

TRANSLOCATION (14;16) POSITIVE MULTIPLE MYELOMA PATIENTS: CLINICAL FEATURES AND SURVIVAL OUTCOMES OF A HIGH-RISK POPULATION.

Published date:
05/17/2018
Excerpt:
Induction therapy consisted of an immunomodulatory drug, a proteasome inhibitor or a combination of both....In the multivariate analysis, baseline hypercalcemia and beta-2-microglobulin >ULN were associated with significantly shorter PFS (HR: 2.3, p=0.02; HR: 2.7, p=0.001, respectively) and OS (HR: 5.4, p<0.001; HR: 1.9, p=0.02, respectively)...